BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Irish Examiner3h
Author interview: A pivot to ‘cosy crime’ requires a high level of literary craftsmanship
The worlds that I’m creating with the detective novels and with 'Learwife' are different. They’re going to do very different ...